Skip to content

CONMED CNMD Cash received from option exercises

Cash received from option exercises at other companies

Globus Medical logo
Globus MedicalGMED
Haemonetics logo
HaemoneticsHAE

Other financials

Income statement

See full
Revenue$317.0M-1.3%
Gross profit$183.4M+3.2%
Operating income$25.4M+59.3%
Net income$13.8M+129%
EPS (diluted)$0.45+137%

Balance sheet

See full
Cash & equivalents$35.0M-1.3%
Total debt$862.6M-3.6%
Total equity$1.0B+4.1%
Total assets$2.3B+0.8%

Cash flow

See full
Operating cash flow$13.5M-67.6%
CapEx$2.9M-23.5%
Free cash flow$10.6M-72.0%

Valuation

See full
Market cap$1.04B-35.6%
Enterprise value$1.87B-24.5%
P/E19×+5.4×
P/S0.8×-0.5×

Profitability

See full
Gross margin55.2%-1.0pp
Operating margin8.2%-5.6pp
Net margin4%-5.0pp
FCF margin9%-3.5pp

Returns & leverage

See full
Return on equity5.5%-7.5pp
Debt / equity0.8×-0.1×
Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: CONMED’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's cash received from option exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CONMED's cash received from option exercises?
CONMED (CNMD) reported cash received from option exercises of $50K in Q4 2025.
How has CONMED's cash received from option exercises changed year-over-year?
CONMED's cash received from option exercises decreased by 94.1% year-over-year, from $850K to $50K.
What is the long-term trend for CONMED's cash received from option exercises?
Over 4 years (2021 to 2025), CONMED's cash received from option exercises has grown at a -68.2% compound annual growth rate (CAGR), from $19.6M to $200K.
What does cash received from option exercises mean?
The cash inflow generated from employees exercising their vested stock options. This serves as a source of liquidity and reflects the alignment between employee compensation and stock price performance.